Comments

Transcript

About this Series

Chronic lymphocytic leukemia (CLL) is now understood to be a complex, heterogeonous disease with tremendous variability between cases. Hematologists use patients’ prognostic risk profiles and individual criteria to decide when to initiate therapy and which firstline therapy to select. Increasingly, targeted oral therapies are preferred over chemotherapy and chemoimmunotherapy. Novel combination therapies and fixed-duration therapies are emerging as new treatment options.

In this six-part series, recognized hematologists from the Arthur G. James Cancer Hospital at The Ohio State University discuss strategies for managing CLL patients who are ready to start therapy after years of monitoring. They explain the latest research around new therapies and combinations, as well as insights from ongoing clinical trials.

Joined by seasoned nurses, physician assistants and other clinicians, experts explore the concerns of CLL patients and share best practices for optimal use of available therapies. Patients open up about the risks and benefits of participating in clinical trials, and talk about how shared decision-making gives them a sense of control over their cancer.

Show More

Who's Who
More on Chronic Lymphocytic Leukemia